



REVISTA DE GASTROENTEROLOGÍA DE MÉXICO

www.elsevier.es/rgmx



ORIGINAL ARTICLE

Colon tumor location: Right side versus left side as a prognostic factor for colon cancer survival: Analysis of a retrospective cohort[☆]



S.P. Molina-Meneses^{a,*}, L.J. Palacios-Fuenmayor^a, F.D. Molina-Mercado^b,
D.F. Caycedo-Medina^c, R. Castaño-Llano^a, L.R. Gómez-Wolff^d, Y.E. Pérez-García^e

^a Servicio de Cirugía Oncológica, Clínica Las Américas, Medellín, Colombia

^b Departamento de Educación Médica, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia

^c Programa de subespecialización en Cirugía Oncológica, Universidad de Antioquia, Medellín, Colombia

^d Servicio de Oncología Clínica, Clínica Las Américas, Medellín, Colombia

^e Servicio de Investigación Aplicada y Epidemiológica, AUNA Ideas, Medellín, Colombia

Received 16 September 2024; accepted 12 December 2024

Available online 12 September 2025

KEYWORDS

Right-sided colon cancer;
Left-sided colon cancer;
Overall survival;
Laterality;
Prognostic factors

Abstract

Introduction: Primary tumor location has emerged as an important prognostic factor due to different biologic characteristics.

Aim: To analyze the prognostic effect of tumor location in patients with colon cancer, comparing right-sided colon cancer with left-sided disease.

Materials and methods: A retrospective cohort study was conducted on patients above 18 years of age operated on for right-sided or left-sided colon cancer within the time frame of January 2016 and June 2022 at a quaternary care hospital. Sociodemographic and histopathologic variables were analyzed. Overall survival and progression-free survival were calculated.

Results: From a total of 247 patients, 145 (58.7%) had right-sided colon cancer and 102 (41.2%) had left-sided disease. Mean age of the right-sided tumor patients was 70 years and mean age of the left-sided tumor patients was 64 years. The majority of the patients were women. Laparoscopic surgery was performed on 71.6% of patients and most of them presented with adenocarcinoma, 68.4% of which were well differentiated tumors. Poorly differentiated tumors were more likely in the right colon than the left, with 9.7% and 0.4%, respectively. Most of the patients did not have lymph node dissemination (N0: 54.7%), but there were more positive lymph nodes (28% vs 16.5%) and more microsatellite instability (48 vs 4 patients) in right-sided tumors.

[☆] This work was presented as an oral communication at the 27th National Congress of the Spanish Association of Coloproctology, organized by the Spanish Association of Coloproctology, held from May 15 to 17, 2024.

* Corresponding author at: Cra. 70 No. 1 -135. Torre 5 Medellín, Colombia. Tel.: (+57) 3013214094.

E-mail addresses: sandrapmolina08@gmail.com, sandrapmolina08@hotmail.com (S.P. Molina-Meneses).

PALABRAS CLAVE

Cáncer de colon derecho;
Cáncer de colon izquierdo;
Supervivencia global;
Lateralidad;
Factores pronósticos

Fifty-three patients presented with metastasis, with no differences regarding laterality. Forty-four patients with right-sided cancer and 18 with left-sided cancer died. Right-sided location was the independent risk variable for overall survival (HR:1.97 [1.10–3.53]). Perineural invasion, metastasis, and disease stage were independent risk variables. Laterality was not a factor in progression-free survival.

Conclusion: Tumor located in the right colon was an independent risk factor impacting overall survival in colon cancer.

© 2025 Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Localización del tumor de colon: derecho versus izquierdo como factor pronóstico para supervivencia en cáncer de colon. Análisis de una cohorte retrospectiva

Resumen

Introducción: La localización del tumor primario ha surgido como factor pronóstico importante debido a distintas características biológicas.

Objetivo: Analizar en pacientes con cáncer de colon el efecto pronóstico de la ubicación del tumor comparando el cáncer de colon derecho vs izquierdo.

Materiales y métodos: Estudio de cohorte retrospectiva, en pacientes mayores de 18a operados por cáncer de colon derecho o izquierdo desde enero/2016 a junio/2022 en hospital de 4to nivel. Se analizaron variables sociodemográficas e histopatológicas. Se calculó supervivencia global y libre de progresión.

Resultados: Total 247 pacientes, 145(58.7%) con cáncer de colon derecho y 102(41.2%) con cáncer de colon izquierdo. Edad promedio: Derecho 70a, izquierdo 64a. La mayoría mujeres. Cirugía laparoscópica en 71.6%. La mayoría de pacientes presentaron adenocarcinomas, 68.4% bien diferenciados. El colon derecho tuvo más probabilidad de tumores mal diferenciados: 9.7% vs 0.4% en izquierdo. La mayoría de pacientes no presentaron diseminación ganglionar N0:54.7%, aunque los tumores derechos presentaron más ganglios positivos 28% vs 16.5% y más inestabilidad de microsatélites: 48 vs 4 pacientes. Presentaron metástasis 53 pacientes, sin diferencias según lateralidad. Murieron 44 pacientes con cáncer derecho y 18 izquierdos. La localización derecha fue variable de riesgo independiente para supervivencia global HR:1,97 (1,10–3,53). La invasión perineural, las metástasis y el estadio de la enfermedad fueron variables independientes de riesgo. En supervivencia libre de progresión la lateralidad no fue factor de riesgo.

Conclusión: Se demuestra que la localización del tumor en colon derecho fue factor de riesgo independiente para la supervivencia global en cáncer de colon.

© 2025 Asociación Mexicana de Gastroenterología. Publicado por Masson Doyma México S.A. Este es un artículo Open Access bajo la CC BY-NC-ND licencia (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Colorectal cancer ranks fourth in cancer-related morbidity and third in cancer-related mortality worldwide, with a reported incidence rate of 19.5% and mortality rate of 9% per 100,000 inhabitants.¹

In the Americas, there are more than 240,000 new colorectal cancer cases annually and approximately 112,000 deaths due to the disease. Likewise, its incidence is expected to increase 60% by 2030. In Colombia, the prevalence of colorectal cancer is 47.57 cases per 100,000 inhabitants and the mortality rate is 4.96 deaths per 100,000 inhabitants. In the past year, the number of new cases reported increased 51%, compared with that reported in 2019, and prevalence increased 23%, compared with the

previous period. There were more cases in women, and the median patient age was 64 years.² In Medellín, cancer was the second cause of death and was responsible for 25% of deaths occurring in the city between 2010 and 2014. Colorectal cancer ranks fourth in morbidity, with an incidence of 7.3% and a mortality rate of 8.1% per 100,000 inhabitants.³

The 5-year survival rate, in general, is 65% but varies from 91% for localized tumors to 73% for locoregionally advanced tumors and 14% for metastatic disease. Only one of every 3 new cases presents with localized disease at the time of diagnosis.⁴

Primary tumor location has emerged as an important prognostic factor due to distinct biologic characteristics, but at present, the side of the colon with cancer is not a

prognostic parameter, that on its own, alters the oncologic management decision.⁵ Petrelli et al. and other authors have shown that right-sided colon cancer is worse than left-sided disease,⁵⁻⁷ in cases of localized disease as well as metastatic disease,^{8,9} demonstrating that they should be considered 2 heterogeneous entities,¹⁰ reporting the need for adequate specialized treatment related to location.⁷ Nevertheless, a Japanese study described a better prognosis for stage I and II right colon tumors, compared with left colon disease.¹¹

The aim of this study was to analyze the prognostic effect of the anatomic location of colon cancer, comparing right-sided and left-sided disease, in a cohort of adult patients with colon cancer operated on and treated at the *Instituto de Cancerología Las Américas AUNA*.

Materials and methods

A retrospective, observational, case-control, analytic cohort study with a survival analysis was conducted on patients admitted to a quaternary care hospital in the city of Medellín, Colombia, within the time frame of January 2016 and June 2022. The STROBE checklist was utilized.

The data were collected from the clinical histories of the patients and the Information System for the Follow-up of Patients with Colorectal Cancer of the *Instituto de Cancerología (IDC) Las Américas AUNA*. The inclusion criteria were patients above 18 years of age with a histologic diagnosis of right-sided or left-sided colon cancer who underwent right hemicolectomy or left hemicolectomy, within the time frame of January 2016 and June 2022.

The sociodemographic variables were age, sex, tobacco use, and body mass index (BMI). Clinical, risk factor, and laboratory variables were analyzed and included the carcinoembryonic antigen (CEA) test result at admission, histologic subtype and grade, clinical stage (TNM 8th edition 2017), tumor location, emergency presentation with bleeding, obstruction or perforation, time between diagnosis and surgical management, number of lymph nodes examined and compromised, tumor size, circumferential resection margin status, perineural and/or lymphovascular invasion, tumor budding, tumor deposits, microsatellite instability, and the KRAS, NRAS, and BRAF somatic mutations. Dates of diagnosis, surgery, last control, recurrence or progression, and death were taken into account for the survival calculation.

Tumor anatomic location (right side vs left side) was the prognostic factor analyzed as the independent variable. Right-sided colon cancer was defined as tumor located in the cecum, ascending colon, or the hepatic angle of the colon and left-sided colon cancer was defined as tumor located in the splenic angle of the colon, descending colon, or sigmoid colon. Patients with pure transverse colon cancer, i.e., those that did not require right or left hemicolectomy due to tumor location, were not included in the study. The primary outcome variables were overall survival, defined as the period from the time of colon cancer diagnosis to the death of the patient due to any cause, and progression-free survival, defined as the period from colon cancer diagnosis to imaging evidence of local or distant disease progression. The administrative censoring data of the study were the patients that did not present with the outcome at the end of the study's follow-up period.

Statistical analysis

The sociodemographic, clinical, and outcome variables were summarized, comparing the patients with right-sided colon cancer and those with left-sided disease. The quantitative variables were expressed as mean and standard deviation, if they met the normality assumption, and when they did not, as median and interquartile range. The qualitative variables were expressed as frequency and percentage. Statistical significance tests were carried out to identify differences between subgroups. For the quantitative variables, this was done with the Student's t test or the Mann-Whitney U test, depending on whether the normality assumption was accepted or rejected. Regarding the qualitative variables, the chi-square test or Fisher's exact test was used for the cases with observations within a crosstab cell less than 5. A survival analysis was carried out through survival curves, comparing patients according to tumor anatomic location (right vs left) for overall survival and progression-free survival. The curves were compared, using the log-rank statistical significance test. A multivariate analysis was carried out to estimate the association of anatomic location with overall survival and progression-free survival. The Cox proportional hazard regression test was used for determining the crude confounding variable-adjusted association, including the clinically important variables and those with a $p < 0.25$ in the univariate analysis, resulting in the final model. The statistical analyses were performed utilizing the SPSS-IBM version 22 (SPSS Inc., Chicago, Illinois, USA) and Rstudio software.

Ethical considerations

The protocol was elaborated according to international ethics norms and the Colombian legislation, and the study was approved and supervised by the Independent Ethics Committee of the *IDC Las Américas AUNA*, which meets the Good Clinical Practice standards in all its activities.

Results

Within the time frame of January 2016 and June 2022, 247 patients with colon cancer were operated on. Of those patients, 145 (58.7%) had right-sided tumors and 102 (41.2%) had left-sided tumors.

The mean age of the patients with right-sided colon cancer was 70 years, which was higher than the mean age of the patients with left-sided colon cancer. Women were the predominant sex in both disease locations.

Table 1 shows the sociodemographic and clinical characteristics of the patients.

Less than 20% of the patients operated on presented with obstruction, perforation, or bleeding prior to surgical management, with no difference regarding tumor laterality. A total of 71.6% of the surgeries were laparoscopic. Of the patients that underwent right hemicolectomy, 34% presented with some type of complication, compared with 30% of the patients that underwent left hemicolectomy.

Regarding the pathology results, the histologic type in more than 98% of the patients with left-sided colon cancer was unspecified adenocarcinoma. In the patients with

Table 1 Sociodemographic and clinical characteristics.

Variable	Right colon (n = 145)	Left colon (n = 102)	Total (n = 247)	P value
Sex, n (%)				
Male	56 (38.6%)	50 (49.0%)	106 (42.9%)	0.118
Female	89 (61.4%)	52 (51.0%)	141 (57.1%)	
Age				
Median (Q ₁ ; Q ₃)	70.0 (60; 78)	64.0 (57; 72.75)	67.0 (58; 76)	0.002
Body mass index				
Median (Q ₁ ; Q ₃)	25.0 (22.22; 27.07)	26.1 (23.68; 28.63)	25.2 (22.78; 27.91)	0.019
Smoking, n (%)				
No	122 (84.1%)	72 (70.6%)	194 (78.5%)	0.012
Yes	23 (15.9%)	30 (29.4%)	53 (21.5%)	
Time between diagnosis and surgery (days)				
Median (Q ₁ ; Q ₃)	74.0 (48; 106)	83.5 (50; 120.5)	77.0 (48; 116)	0.294
Type of surgery, n (%)				
Open	49 (33.8%)	22 (21.6%)	71 (28.7%)	0.045
Laparoscopic	96 (66.2%)	80 (78.4%)	176 (71.3%)	
Positive resection margin, n (%)				
No	137 (94.5%)	101 (99.0%)	238 (96.4%)	0.085
Yes	8 (5.5%)	1 (1.0%)	9 (3.6%)	
Number of lymph nodes examined ≥ 12, n (%)				
No	2 (1.4%)	13 (12.7%)	15 (6.1%)	0.001
Yes	143 (98.6%)	89 (87.3%)	232 (93.9%)	
Histology, n (%)				
Nonspecified adenocarcinoma	118 (81.4%)	100 (98.0%)	218 (88.3%)	0.001
Signet ring cell adenocarcinoma	5 (3.4%)	0 (0%)	5 (2.0%)	
Mucinous adenocarcinoma	19 (13.1%)	2 (2.0%)	21 (8.5%)	
GIST	1 (0.7%)	0 (0%)	1 (0.4%)	
Neuroendocrine tumor	2 (1.4%)	0 (0%)	2 (0.8%)	
Differentiation grade, n (%)				
Well differentiated	90 (62.1%)	79 (77.5%)	169 (68.4%)	0.001
Moderately differentiated	31 (21.4%)	22 (21.6%)	53 (21.5%)	
Poorly differentiated	24 (16.6%)	1 (1.0%)	25 (10.1%)	
Stage, n (%)				
I	15 (10.3%)	17 (16.7%)	32 (13.0%)	0.258
II	58 (40.0%)	42 (41.2%)	100 (40.5%)	
III	57 (39.3%)	38 (37.3%)	95 (38.5%)	
IV	15 (10.3%)	5 (4.9%)	20 (8.1%)	
Tumor size ≥ 50 mm, n (%)				
No	32 (22.1%)	45 (44.1%)	77 (31.2%)	0.001
Yes	113 (77.9%)	57 (55.9%)	170 (68.8%)	
Lymph node stratification, n (%)				
N0	74 (51.0%)	61 (59.8%)	135 (54.7%)	0.408
N1	41 (28.3%)	24 (23.5%)	65 (26.3%)	
N2	30 (20.7%)	17 (16.7%)	47 (19.0%)	
Perineural invasion, n (%)				
No	120 (82.8%)	81 (79.4%)	201 (81.4%)	0.511
Yes	25 (17.2%)	21 (20.6%)	46 (18.6%)	
Lymphovascular invasion, n (%)				
No	104 (71.7%)	84 (82.4%)	188 (76.1%)	0.068
Yes	41 (28.3%)	18 (17.6%)	59 (23.9%)	
Tumor deposits, n (%)				
No	130 (89.7%)	90 (88.2%)	220 (89.1%)	0.836
Yes	15 (10.3%)	12 (11.8%)	27 (10.9%)	
Microsatellite instability, n (%)				
No	97 (66.9%)	98 (96.1%)	195 (78.9%)	0.001
Yes	48 (33.1%)	4 (3.9%)	52 (21.1%)	

Table 1 (Continued)

Variable	Right colon (n = 145)	Left colon (n = 102)	Total (n = 247)	P value
<i>Identified mutation, n (%)</i>				
No	123 (84.8%)	94 (92.2%)	217 (87.9%)	0.112
Yes	22 (15.2%)	8 (7.8%)	30 (12.1%)	
<i>Adjuvant treatment, n (%)</i>				
No	68 (46.9%)	47 (46.1%)	115 (46.6%)	1
Yes	77 (53.1%)	55 (53.9%)	132 (53.4%)	
<i>Metastasis, n (%)</i>				
No	116 (80.0%)	78 (76.5%)	194 (78.5%)	0.531
Yes	29 (20.0%)	24 (23.5%)	53 (21.5%)	
<i>Metastasis site, n (%)</i>				
None	116 (80.0%)	78 (76.5%)	194 (78.5%)	0.721
Liver	17 (11.7%)	13 (12.7%)	30 (12.1%)	
Peritoneum	6 (4.1%)	3 (2.9%)	9 (3.6%)	
Lung	3 (2.1%)	5 (4.9%)	8 (3.2%)	
Lymph node	3 (2.1%)	3 (2.9%)	6 (2.4%)	

GIST: Gastrointestinal stromal tumor.

The p values in bold print are the statistically significant values.

right-sided colon cancer, signet ring cell adenocarcinoma was identified in 5 patients and mucinous adenocarcinoma in 19 patients. Only one patient presented with GIST and 2 patients with neuroendocrine tumors, and all 3 of those tumors were on the right side.

Most of the study patients (68.4%) had well differentiated tumors, 36.4% of which were right-sided and 31.9% left-sided. The patients with right-sided colon cancer were more likely to have poorly differentiated tumors, at 9.7%, compared with the patients with left-sided colon cancer, at 0.4%, and the difference was statistically significant.

Of the patients with right-sided colon cancer, 78% had tumors larger than 50 mm, compared with 57% of the patients with left-sided colon cancer. Ninety-nine percent of the patients with right-sided colon cancer had more than 12 lymph nodes in the pathology report, compared with 87% of the patients with left-sided colon cancer.

The majority of cases did not have dissemination to the lymph nodes; 135 of the 247 patients were N0 (54.6%). The patients with right-sided colon cancer presented with a higher number of positive lymph nodes (n = 71; 28%), compared with the patients with left-sided colon cancer (n = 41; 16.5%).

There were no significant differences in tumor stage at the time of surgery. More than half of the patients were in stage II or III, according to the 8th classification of the American Joint Committee on Cancer (AJCC). Twenty patients had metastatic disease at the time of surgery, 15 of whom had right-sided colon cancer, and the main reason for surgery at that stage was intestinal obstruction. Six percent of the patients with right-sided colon cancer had positive resection margins, as did 1% of the patients with left-sided colon cancer. Perineural invasion was more frequent in patients with left-sided colon cancer (21%), and less frequent in patients with right-sided disease (17%), with no statistical significance. In contrast, lymphovascular invasion was more frequent in the right colon (28%), compared with the left colon (18%), and the difference was statistically significant

(p = 0.03). Forty-eight patients with right-sided colon cancer and 4 patients with left-sided colon cancer presented with microsatellite instability, with a statistically significant difference (p = 0.001). K-RAS, N-RAS, and BRAF mutations were reported in only 30 patients, and tumor laterality was not identified.

Thirty-three patients presented with metastasis during follow-up and the most common site was the liver. Other common sites of metastasis were the peritoneum and lung. There were no statistically significant differences with respect to tumor laterality.

There were 44 deaths (30%) in the patients with right-sided colon cancer and 18 deaths (12%) in the patients with left-sided colon cancer. Upon comparing overall survival according to tumor laterality, the patients with right-sided colon cancer had worse overall survival with a statistically significant p value (Fig. 1). For progression-free survival, there were no differences, according to tumor laterality (Fig. 2).

Tables 2 and 3 show the results of the univariate and multivariate analyses by outcome.

Discussion

Our study produced several important results. First, it showed that right-sided colon cancer was an independent risk variable for overall survival, with a HR of 1.97 (1.10–3.53). In addition, age at diagnosis, perineural invasion, metastasis, and disease stage were other independent risk variables found in the multivariate analysis. Disease stage IV was the most important risk factor, with an adjusted HR of 13.87 (2.39–80.57).

Specifically regarding progression-free survival results, in which laterality was not a risk factor, the presence of tumor deposits, positive lymph nodes, and mutations were independent risk factors. The presence of mutations was the most important risk factor, with a HR of 6.26 (3.30–11.87).




Figure 1 Overall survival. Log-rank 0.01.

Lim et al. reported clinical and pathologic differences in right-sided colon cancer, compared with left-sided disease.⁷ They demonstrated the impact of tumor location on the overall survival results, with better survival rates in patients with left-sided colon cancer, compared with right-sided colon cancer, but there were no statistically significant differences regarding progression-free survival.

Among the characteristics associated with survival, advanced age at diagnosis has been shown to be a significant predictor of worse overall survival and cause of death different from tumor progression,¹² mainly in patients above 65–70 years of age.¹³ However, there are studies in which an earlier presentation age (<50 years) was associated with advanced stages and greater recurrence, but with similar survival.¹⁴ In our study, the patients with right-sided colon cancer had a higher median age (70 years), compared with patients with left-sided disease (64 years), at the time of diagnosis, and that difference was statistically significant. The univariate analysis demonstrated a slight prognostic effect, but that association was not shown in the multivariate analysis with either overall survival or progression-free survival.

Female sex has been a factor associated with greater survival in colorectal cancer,^{15,16} but in our cohort, a prognostic effect related to sex was not identified. A low BMI was reported as a predictor of negative outcomes,¹⁷ even though a BMI > 35 kg/m² emerged as a risk factor for postoperative complications and death.^{18,19} In our analysis, there were no differences between the 2 groups related to weight.

Smoking has also been associated with a worse prognosis, albeit with inconclusive results.²⁰ In our cohort, there was

a greater prevalence of cigarette smoking in patients with left-sided colon cancer (29%) than in patients with right-sided colon cancer (15.9%), with no prognostic effect related to smoking. There can be acute complications in colon cancer, such as bleeding, obstruction, and perforation,²¹ and they are associated with worse prognosis.^{22,23} We found no differences between our study patients who presented with said complications. The time lapse between diagnosis and surgery has been described as a factor, with reports finding that an interval of more than 4 weeks was independently related to worse overall survival.^{24,25} In our series, the mean time from diagnosis to surgery was over 3 months, reported for both sides of the colon, with no differences in survival, most likely attributable to the delay in performing the procedure in general.

More advanced stages of disease have a worse prognosis.²⁶ In our study, we found no differences in stages in the patients of either group. In the univariate and multivariate analyses, presenting with stage IV importantly affected survival.

The site of metastasis has also been reported to affect prognosis. A study described a higher probability of 3-year survival only in patients with metastasis to the lungs, compared with other sites.²⁷ Sjo et al. found a higher incidence of peritoneal carcinomatosis in right-sided colon cancer than in left-sided disease, with a mean survival of 8 months.^{28,29} In our study, there were no differences in metastatic sites in the 2 groups, nor was there a prognostic relation to the site of metastasis, but not presenting with metastasis was indeed related to better survival, with a statistically significant p value.




Figure 2 Progression-free survival. Log-rank 0.975.

Even though elevated preoperative CEA has been described as a predictor of poor prognosis, its significance for predicting long-term outcomes is not clear.^{30,31} CEA was not determined in more than 50% of our study patients, and so we could not reach a conclusion about its relation to prognosis.

Regarding the histopathologic variables, more than 90% of our study patients presented with adenocarcinoma, a finding consistent with that in the national and international literature.^{32,33} Mucinous and signet ring cell cancers are usually considered independent factors of poor survival.^{34,35} In our study, there was a greater presence of those 2 cancer types in the patients with right-sided tumors ($n=24$), compared with the patients with left-sided tumors ($n=2$). The univariate analysis showed no prognostic relation to those two histologic types.

Histologic differentiation grade significantly affects survival and is associated with higher stage, risk of metastasis, and death.^{36,37} In our study, the patients with right-sided colon cancer presented with more tumors that had some degree of dedifferentiation, compared with the patients with left-sided colon cancer. In the univariate analysis, patients with moderately or poorly differentiated tumors had a worse prognosis than the patients with well differentiated tumors, but that finding was not reflected in the multivariate analysis.

In addition, the number of lymph nodes analyzed has been shown to have a positive association with better survival.³⁸ In the present study, 99% of the patients with right-sided colon cancer had a minimum of 12 lymph nodes analyzed as the surgical quality criterion, compared with 87% of the patients with left-sided colon cancer. That difference was not associated with differences in survival.

In their publications, Dai et al. and Kornprat et al. related a higher tumor diameter to worse prognosis and survival.^{39,40} In our cohort, the majority of patients with right-sided colon cancer had tumors larger than 50 mm ($n=113$, 78%), compared with the patients with left-sided disease ($n=57$, 56%), but the difference was not related to survival.

A positive circumferential resection margin has been found to be a strong indicator of poor prognosis, regardless of stage.^{41,42} Malignant longitudinal resection margin involvement has been described as a predictor of local recurrence, the development of distant metastasis, and reduced disease-free survival.⁴³ In our patients, 6% of the resected margins were compromised in the patients with right-sided colon cancer and 1% in the patients with left-sided colon cancer, with no statistically significant difference or prognostic relation between the 2 groups.

Mayo et al., Liebig et al., and Fujita et al. reported perineural invasion as a poor prognosis factor, upon its association with lower overall survival.^{44–46} However, there are

Table 2 Univariate and multivariate analyses of independent risk factors for overall survival.

Variable	Univariate		Multivariate	
	HR (95% CI for HR)	p value	HR (95% CI for HR)	p value
<i>Right colon</i>	2.04 (1.18–3.52)	0.011	2.14 (1.15–3.99)	0.016
<i>Women</i>	0.71 (0.43–1.18)	0.187	0.86 (0.49–1.50)	0.600
<i>Age at diagnosis</i>	1.02 (1.00–1.04)	0.033	1.03 (1.00–1.05)	0.033
<i>Body mass index</i>	0.95 (0.9–1.02)	0.17	0.93 (0.87–1.00)	0.082
<i>Smoking</i>	1.15 (0.64–2.02)	0.64		
<i>Time between diagnosis and surgery</i>	0.99 (0.99–1.00)	0.673		
<i>Number of lymph nodes examined ≥ 12</i>	0.83 (0.33–2.09)	0.705		
<i>Tumor size ≥ 50 mm</i>	0.95 (0.55–1.63)	0.863		
<i>Compromised resection margin</i>	3.26 (1.30–8.17)	0.012	1.38 (0.44–4.31)	0.573
<i>Perineural invasion</i>	2.16 (1.24–3.76)	0.006	3.62 (1.67–7.82)	0.001
<i>Lymphovascular invasion</i>	2.51 (1.50–4.20)	0.001	0.91 (0.45–1.82)	0.800
<i>Tumor deposits</i>	2.80 (1.47–5.34)	0.002	0.99 (0.43–2.27)	0.986
<i>Microsatellite instability</i>	0.67 (0.34–1.32)	0.251		
<i>Identified mutation</i>	2.74 (1.54–4.85)	0.001	0.44 (0.19–1.04)	0.062
<i>Adjuvant treatment</i>	0.69 (0.42–1.15)	0.16	0.31 (0.16–0.57)	0.001
<i>Metastasis</i>	5.18 (3.12–8.59)	0.001	4.78 (2.42–9.43)	0.001
<i>Differentiation grade</i>				
Moderately differentiated	1.99 (1.11–3.58)	0.02	2.08 (1.07–4.01)	0.029
Poorly differentiated	2.73 (1.35–5.55)	0.005	1.415 (0.60–3.29)	0.420
<i>Stage</i>				
Stage II	3.09 (0.72–13.22)	0.126	3.16 (0.72–13.86)	0.127
Stage III	4.09 (0.95–17.46)	0.057	4.44 (0.96–20.54)	0.056
Stage IV	20.86 (4.81–90.46)	0.001	13.87 (2.37–80.93)	0.003
<i>Positive lymph nodes</i>				
N1	1.76 (0.96–3.24)	0.065		
N2	3.12 (1.71–5.70)	0.001		
<i>Poor prognosis histology</i>				
Signet ring cell adenocarcinoma	2.13 (0.66–6.84)	0.204		
Mucinous adenocarcinoma	1.88 (0.89–3.96)	0.096		
GIST	1.14 (0.0–Infinito)	0.99		
Neuroendocrine tumor	1.14 (0.0–Infinito)	0.99		
<i>Metastasis site</i>				
None	0.19 (0.06–0.57)	0.002		
Liver	1.24 (0.42–3.63)	0.691		
Peritoneum	1.15 (0.33–3.94)	0.819		
Lung	0.44 (0.09–1.98)	0.287		

GIST: gastrointestinal stromal tumor; HR: hazard ratio; 95% CI: 95% confidence interval. The p values in bold print are the statistically significant values.

publications in which it has not been found to be an independent predictive factor in nonmetastatic colon cancer.^{47,48} Similarly, lymphovascular invasion is associated with poor prognosis.^{47,49} In the present study, 17% of the patients with right-sided colon cancer and 21% with left-sided disease had perineural invasion, with no differences between the groups ($p = 0.512$) and no differences in lymphovascular invasion, which was present in 28% of the patients with right-sided colon cancer and 18% of the patients with left-sided colon cancer ($p = 0.068$). The univariate analysis showed that those 2 variables could have a prognostic effect, but in the multivariate analysis, only perineural invasion remained statistically significant.

An association between the presence of tumor deposits and a decrease in overall survival has been shown.^{50,51} In our study, there were no differences in the presence of tumor

deposits between the 2 groups, nor was a prognostic relation found.

The presence of microsatellite instability that is related to defects in the mismatch repair pathway, resulting in hereditary nonpolyposis colorectal cancer syndrome, or Lynch syndrome,⁵² has been associated with better oncologic outcomes regarding survival time and disease-free time.^{53,54} Gryfe et al. reported that colorectal cancers with microsatellite instability had a 5-year survival of 74%, compared with 54% of other cancers, results that were statistically significant and maintained at all disease stages.⁵⁵ In our cohort, there was a greater presence of microsatellite instability in the patients with right-sided colon cancer (33%), compared with the 4% in the patients with left-sided colon cancer. The difference between the 2 groups was

Table 3 Univariate and multivariate analyses of independent risk factors for progression-free survival.

Variable	Univariate		Multivariate	
	HR (95% CI for HR)	p value	HR (95% CI for HR)	p value
<i>Right colon</i>	0.89 (0.52–1.54)	0.693	0.66 (0.36–1.21)	0.180
<i>Women</i>	0.58 (0.34–1.01)	0.055	0.61 (0.32–1.14)	0.126
<i>Age at diagnosis</i>	0.99 (0.97–1.02)	0.701		
<i>Body mass index</i>	0.96 (0.90–1.03)	0.234	0.96 (0.90–1.03)	0.334
<i>Smoking</i>	2.15 (1.23–3.77)	0.008	1.72 (0.90–3.31)	0.098
<i>Time between diagnosis and surgery</i>	1 (0.99–1.00)	0.945		
<i>Number of lymph nodes examined ≥ 12</i>	0.60 (0.24–1.53)	0.292		
<i>Tumor size ≥ 50 mm</i>	0.87 (0.49–1.54)	0.639		
<i>Compromised resection margin</i>	2.73 (0.98–7.58)	0.053	1.06 (0.33–3.37)	0.910
<i>Perineural invasion</i>	1.28 (0.67–2.44)	0.446		
<i>Lymphovascular invasion</i>	3.09 (1.79–5.32)	0.001	1.95 (0.97–3.94)	0.060
<i>Tumor deposits</i>	4.08 (2.21–7.54)	0.001	2.52 (1.27–5.5)	0.008
<i>Microsatellite instability</i>	0.59 (0.28–1.27)	0.179		
<i>Identified mutation</i>	6.11 (3.5–10.7)	0.001	6.26 (3.30–11.87)	0.001
<i>Adjuvant treatment</i>	1.57 (0.89–2.75)	0.116	0.59 (0.28–1.20)	0.149
<i>Differentiation grade</i>				
Moderately differentiated	1.79 (0.96–3.31)	0.064		
Poorly differentiated	1.65 (0.72–3.76)	0.228		
<i>Positive lymph nodes</i>				
N1	2.94 (1.48–5.84)	0.001	2.88 (1.25–6.70)	0.012
N2	5.31 (2.71–10.41)	0.001	3.94 (1.59–9.76)	0.002
<i>Poor prognosis histology</i>				
Signet ring cell adenocarcinoma	1.58 (0.38–6.53)	0.523		
Mucinous adenocarcinoma	0.96 (0.34–2.69)	0.95		
GIST	0.00 (0–Inf)	0.99		
Neuroendocrine tumor	2.30 (0.31–16.73)	0.4		

GIST: gastrointestinal stromal tumor; HR: hazard ratio; 95% CI: 95% confidence interval.

The p values in bold print are the statistically significant values.

statistically significant ($p=0.001$), but the presence of the alteration was not related to survival.

KRAS gene mutations have been shown to be present in 20–60% of colorectal cancer cases.⁵⁶ Shen et al. reported on a cohort of patients in which KRAS was more frequently mutated in patients with right-sided colon cancer.⁵⁶ In other studies, the KRAS and NRAS mutations were independently correlated with worse prognosis,^{57–59} but that is not a unanimous finding.^{60–62} In our study, we found information related to those mutations in only 23% of the entire cohort, with no differences between groups or relation to survival.

Among the limitations of our study is its historic character, which may have led to nondifferential measuring bias, which could alter the quality of the results. In addition, we did not carry out multiplicity hypothesis tests, and so there is a risk of type 1 error, i.e., finding differences when there actually are none. Nevertheless, we consider said risk could have been mitigated in the multivariate analysis. Another limitation is the sample size, given that at least 14 independent variables were found in the multivariate analysis, likely making other studies with larger samples necessary for corroborating the results.

There may be a cohort effect during the 2016–2022 study period due to the COVID-19 pandemic, which could have affected the quality of healthcare and the survival prognosis.

Strengths of our study include a significant collection period, compliance with the College of American Pathologists cancer protocol, and the availability of a staff exclusively dedicated to patient records, resulting in an insignificant number of lost data in the database. In addition, a rigorous multivariate analysis was performed, determining that tumor laterality was a risk factor independent from other already known prognostic factors. In addition, because the study was conducted at a cancer referral center, the processes are standardized, with quality criteria, such as having more than 12 lymph nodes analyzed, which occurred in a large number of our study patients. Furthermore, the majority of surgical procedures were performed via laparoscopy.

In conclusion, the location of cancer in the right colon was shown to be an independent risk factor that negatively impacts overall survival in colon cancer.

Ethical considerations

The protocol was elaborated according to international ethics norms and the Colombian legislation, and the study was approved and supervised by the Independent Ethics Committee of the IDC Las Américas AUNA, which meets the Good Clinical Practice standards in all its activities.

The authors declare this article contains no information that could identify patients, and so informed consent was not required for the publication of this article.

No experiments on humans or animals were conducted for this research.

Funding

The funding of this study was based on the authors' own resources.

Declaration of competing interest

The authors declare that there are no conflicts of interest.

References

- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021;71:209–49, <http://dx.doi.org/10.3322/caac.21660>.
- Situación del cáncer en la población adulta atendida en el SGSSS de Colombia 2022 [internet]. [Accessed 1 January 2024]. Available from: <https://cuentadealcosto.org/publicaciones/situacion-del-cancer-en-la-poblacion-adulta-atendida-en-el-sgsss-de-colombia-2022/>.
- Brome-Bohórquez MR, Montoya-Restrepo DM, Salcedo A. Cancer incidence and mortality in Medellín, Colombia. *Colomb Med (Cali)*. 2018;49:81–8, <http://dx.doi.org/10.25100/cm.v49i1.3740>.
- American Cancer Society, Available from: In: Cancer Facts & Figures 2023. Atlanta: American Cancer Society; 2023 <https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2023-cancer-facts-figures.html>
- Petrelli F, Tomasello G, Borronovo K, et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. *JAMA Oncol*. 2017;3:211–9, <http://dx.doi.org/10.1001/jamaoncol.2016.4227>.
- Wang S, Xu X, Guan J, et al. Better survival of right-sided than left-sided stage II colon cancer: a propensity scores matching analysis based on SEER database. *Turk J Gastroenterol*. 2020;31:805–13, <http://dx.doi.org/10.5152/tjg.2020.19531>.
- Lim DR, Kuk JK, Kim T, Available from: Comparison of oncological outcomes of right-sided colon cancer versus left-sided colon cancer after curative resection. *Medicine (United States)* [Internet]. 2017 https://journals-lww-com.udea.lookproxy.com/mdjournal/fulltext/2017/10200/comparison_of_oncological_outcomes_of_right_sided.50.aspx
- Holch JW, Ricard I, Stintzing S, Available from: The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. *Eur J Cancer* [Internet]. 2017;70:87–98 www.sciencedirect.com
- Loupakis F, Yang D, Yau L, et al, Available from: Primary tumor location as a prognostic factor in metastatic colorectal cancer. *J Natl Cancer Inst* [Internet]. 2015;107:427 <https://academic.oup.com/jnci/article/107/3/dju427/913509>
- Shen H, Yang J, Huang Q, et al, Available from: Different treatment strategies and molecular features between right-sided and left-sided colon cancers 2015 *Advances in Colorectal Cancer*. *World J Gastroenterol* [Internet]. 2015;21:6470–8 <http://www.wjgnet.com/esps/HelpDesk:http://www.wjgnet.com/esps/helpdesk.aspx>
- Moritani K, Hasegawa H, Okabayashi K, et al. Difference in the recurrence rate between right-and left-sided colon cancer: a 17-year experience at a single institution. *Surg Today*. 2024;44:1685–91, <http://dx.doi.org/10.1007/s00595-013-0748-5>.
- Van Eeghen EE, Bakker SD, van Bochove A, et al. Impact of age and comorbidity on survival in colorectal cancer. *J Gastrointest Oncol*. 2015;6:605, <http://dx.doi.org/10.3978/j.issn.2078-6891.2015.070>.
- Aguiar-Junior S, de Oliveira MM, Silva DRME, et al. Survival of patients with colorectal cancer in a cancer center. *Arq Gastroenterol*. 2020;57:172–7, <http://dx.doi.org/10.1590/S0004-2803.202000000-32>.
- Steele SR, Park GE, Johnson EK, et al. The impact of age on colorectal cancer incidence, treatment, and outcomes in an equal-access health care system. *Dis Colon Rectum*. 2014;57:303–10, <http://dx.doi.org/10.1097/DCR.0b013e3182a586e7>.
- Majek O, Gondos A, Jansen L, et al. Sex differences in colorectal cancer survival: population-based analysis of 164,996 colorectal cancer patients in Germany. *PLoS One*. 2013;8:e68077, <http://dx.doi.org/10.1371/journal.pone.0068077>.
- Hendifar A, Yang D, Lenz F, et al. Gender disparities in metastatic colorectal cancer survival. *Clin Cancer Res*. 2009;15:6391–7, <http://dx.doi.org/10.1158/1078-0432.CCR-09-0877>.
- Shahjehan F, Merchea A, Cochuyt JJ, et al. Body mass index and long-term outcomes in patients with colorectal cancer. *Front Oncol*. 2018;8:620, <http://dx.doi.org/10.3389/fonc.2018.00620>.
- Daniel CR, Shu X, Ye Y, et al. Severe obesity prior to diagnosis limits survival in colorectal cancer patients evaluated at a large cancer centre. *Br J Cancer*. 2016;114:103–9, <http://dx.doi.org/10.1038/bjc.2015.424>.
- Merkow RP, Bilimoria KY, McCarter MD, et al. Effect of body mass index on short-term outcomes after colectomy for cancer. *J Am Coll Surg*. 2009;208:53–61, <http://dx.doi.org/10.1016/j.jamcollsurg.2008.08.032>.
- Walter V, Jansen L, Hoffmeister M, et al. Smoking and survival of colorectal cancer patients: systematic review and meta-analysis. *Ann Oncol*. 2014;25:1517–25, <http://dx.doi.org/10.1093/annonc/mdu040>.
- Yang X-F, Pan K. Diagnosis and management of acute complications in patients with colon cancer: bleeding, obstruction, and perforation. *Chin J Cancer Res*. 2014;26:331–40, <http://dx.doi.org/10.3978/j.issn.1000-9604.2014.06.11>.
- Biondo S, Kreisler E, Millan M, et al. Differences in patient postoperative and long-term outcomes between obstructive and perforated colonic cancer. *Am J Surg*. 2008;195:427–32, <http://dx.doi.org/10.1016/j.amjsurg.2007.02.027>.
- Biondo S, Marti-Ragué J, Kreisler E, et al. A prospective study of outcomes of emergency and elective surgeries for complicated colonic cancer. *Am J Surg*. 2005;189:377–83, <http://dx.doi.org/10.1016/j.amjsurg.2005.01.009>.
- Whittaker TM, Abdelrazek MEG, Fitzpatrick AJ, et al. Delay to elective colorectal cancer surgery and implications for survival: a systematic review and meta-analysis. *Colorectal Dis*. 2021;23:1699–711, <http://dx.doi.org/10.1111/codi.15625>.
- Kaltenmeier C, Shen C, Medich DS, et al. Time to surgery and colon cancer survival in the United States. *Ann Surg*. 2021;274:1025–31, <http://dx.doi.org/10.1097/SLA.0000000000003745>.
- Lee C-H, Cheng S-C, Tung H-Y, et al. The risk factors affecting survival in colorectal cancer in taiwan. *Iran J Public Health*. 2018;47:519–30. PMID: 29900136.
- Wang J, Li S, Liu Y, et al. Metastatic patterns and survival outcomes in patients with stage IV colon cancer: a population-based analysis. *Cancer Med*. 2020;9:361–73, <http://dx.doi.org/10.1002/cam4.2673>.
- Sjo OH, Berg M, Merok MA, et al. Peritoneal carcinomatosis of colon cancer origin: highest incidence in women and in

- patients with right-sided tumors. *J Surg Oncol.* 2011;104:792–7, <http://dx.doi.org/10.1002/jso.21959>.
29. Lemmens VE, Klaver YL, Verwaal VJ, et al. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. *Int J Cancer.* 2011;128:2717–25, <http://dx.doi.org/10.1002/ijc.25596>.
 30. Kim CG, Ahn JB, Jung M, et al. Preoperative serum carcinoembryonic antigen level as a prognostic factor for recurrence and survival after curative resection followed by adjuvant chemotherapy in stage III colon cancer. *Ann Surg Oncol.* 2017;24:227–35, <http://dx.doi.org/10.1245/s10434-016-5613-5>.
 31. Kirat HT, Ozturk E, Lavery IC, et al. The predictive value of preoperative carcinoembryonic antigen level in the prognosis of colon cancer. *Am J Surg.* 2012;204:447–52, <http://dx.doi.org/10.1016/j.amjsurg.2011.11.007>.
 32. Campo-Sánchez SM, Camargo-Trillos J, Calle-Ramírez JA, et al. Colorectal cancer survival at an oncologic center in Colombia. A historic cohort study. *Rev Gastroenterol Mex (Engl Ed).* 2019;84:174–84, <http://dx.doi.org/10.1016/j.rgmex.2018.04.002>.
 33. Sibio S, Di Giorgio A, D'Ugo S, et al. Histotype influences emergency presentation and prognosis in colon cancer surgery. *Langenbecks Arch Surg.* 2019;404:841–51, <http://dx.doi.org/10.1007/s00423-019-01826-6>.
 34. Yang L-L, Wang M, He P. Clinicopathological characteristics and survival in colorectal signet ring cell carcinoma: a population-based study. *Sci Rep.* 2020;10:10460, <http://dx.doi.org/10.1038/s41598-020-67388-6>.
 35. Arifi S, Elmesbahi O, Riffi AA. Primary signet ring cell carcinoma of the colon and rectum. *Bull Cancer.* 2015;102:880–8, <http://dx.doi.org/10.1016/j.bulcan.2015.07.005>.
 36. Compton CC. Colorectal carcinoma: diagnostic, prognostic, and molecular features. *Mod Pathol.* 2003;16:376–88, <http://dx.doi.org/10.1097/01.MP.0000062859.46942.93>.
 37. Halvorsen TB, Seim E. Degree of differentiation in colorectal adenocarcinomas: a multivariate analysis of the influence on survival. *J Clin Pathol.* 1988;41:532–7, <http://dx.doi.org/10.1136/jcp.41.5.532>.
 38. Le Voyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. *J Clin Oncol.* 2003;21:2912–9, <http://dx.doi.org/10.1200/JCO.2003.05.062>.
 39. Dai W, Li Y, Meng X, et al. Does tumor size have its prognostic role in colorectal cancer? Re-evaluating its value in colorectal adenocarcinoma with different macroscopic growth pattern. *Int J Surg.* 2017;45:105–12, <http://dx.doi.org/10.1016/j.ijss.2017.07.100>.
 40. Kornprat P, Pollheimer MJ, Lindtner RA, et al. Value of tumor size as a prognostic variable in colorectal cancer: a critical reappraisal. *Am J Clin Oncol.* 2011;34:43–9, <http://dx.doi.org/10.1097/COC.0b013e3181cae8dd>.
 41. Tang X-Y, Huang M-X, Han S-Q, et al. The circumferential resection margin is a prognostic predictor in colon cancer. *Front Oncol.* 2020;10, <http://dx.doi.org/10.3389/fonc.2020.00927>.
 42. Amri R, Bordeianou LG, Sylla P, et al. Association of radial margin positivity with colon cancer. *JAMA Surg.* 2015;150:890–8, <http://dx.doi.org/10.1001/jamasurg.2015.1525>.
 43. Balbaa MA, Elkady N, Abdelrahman EM. Predictive factors of positive circumferential and longitudinal margins in early T3 colorectal cancer resection. *Int J Surg Oncol.* 2020;2020:6789709, <http://dx.doi.org/10.1155/2020/6789709>.
 44. Mayo E, Llanos AAM, Yi X, et al. Prognostic value of tumour deposit and perineural invasion status in colorectal cancer patients: a SEER-based population study. *Histopathology.* 2016;69:230–8, <http://dx.doi.org/10.1111/his.12936>.
 45. Liebig C, Ayala G, Wilks JA, et al. Perineural invasion in cancer: a review of the literature. *Cancer.* 2009;115:3379–91, <http://dx.doi.org/10.1002/cncr.24396>.
 46. Fujita S, Shimoda T, Yoshimura K, et al. Prospective evaluation of prognostic factors in patients with colorectal cancer undergoing curative resection. *J Surg Oncol.* 2003;84:127–31, <http://dx.doi.org/10.1002/jso.10308>.
 47. Hu G, Li L, Hu K. Clinical implications of perineural invasion in patients with colorectal cancer. *Medicine.* 2020;99:E19860, <http://dx.doi.org/10.1097/MD.00000000000019860>.
 48. Leijssen LGJ, Dinaux AM, Taylor MS, et al. Perineural invasion is a prognostic but not a predictive factor in non-metastatic colon cancer. *Dis Colon Rectum.* 2019;62:1212–21, <http://dx.doi.org/10.1007/DCR.0b013e3181cf8ae5>.
 49. Lim S-B, Yu CS, Jang SJ, et al. Prognostic significance of lymphovascular invasion in sporadic colorectal cancer. *Dis Colon Rectum.* 2010;53:377–84, <http://dx.doi.org/10.1007/DCR.0b013e3181cf8ae5>.
 50. Basnet S, Lou Q-F, Liu N, et al. Tumor deposit is an independent prognostic indicator in patients who underwent radical resection for colorectal cancer. *J Cancer.* 2018;9:3979–85, <http://dx.doi.org/10.7150/jca.27475>.
 51. Ueno H, Hashiguchi Y, Shimazaki H, et al. Peritumoral deposits as an adverse prognostic indicator of colorectal cancer. *Am J Surg.* 2014;207:70–7, <http://dx.doi.org/10.1016/j.amjsurg.2013.04.009>.
 52. Nguyen LH, Goel A, Chung DC. Pathways of colorectal carcinogenesis. *Gastroenterology.* 2020;158:291–302, <http://dx.doi.org/10.1053/j.gastro.2019.08.059>.
 53. Kawakami H, Zaanani A, Sinicrope FA. Microsatellite instability testing and its role in the management of colorectal cancer. *Curr Treat Options Oncol.* 2015;16:30, <http://dx.doi.org/10.1007/s11864-015-0348-2>.
 54. Petrelli F, Ghidini M, Cabiddu M, et al. Microsatellite instability and survival in stage II colorectal cancer: a systematic review and meta-analysis. *Anticancer Res.* 2019;39:6431–41, <http://dx.doi.org/10.21873/anticancer.13857>.
 55. Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. *N Engl J Med.* 2000;342:69–77, <http://dx.doi.org/10.1056/NEJM200001133420201>.
 56. Shen H, Yuan Y, Hu H-G, et al. Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients. *World J Gastroenterol.* 2011;17:809–16, <http://dx.doi.org/10.3748/wjg.v17.i6.809>.
 57. Morgan Z, Chow BE, Strong EA, et al. RAS mutation status confers prognostic relevance in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer. *J Surg Res.* 2019;240:130–5, <http://dx.doi.org/10.1016/j.jss.2019.02.050>.
 58. Péron J, Mercier F, Tuech J-J, et al. The location of the primary colon cancer has no impact on outcomes in patients undergoing cytoreductive surgery for peritoneal metastasis. *Surgery.* 2019;165:476–84, <http://dx.doi.org/10.1016/j.surg.2018.07.027>.
 59. Baratti D, Kusamura S, Nigam M, et al. Prognostic impact of primary site and RAS/RAF mutations in a surgical series of colorectal cancer with peritoneal metastases. *Ann Surg Oncol.* 2021;28:3332–42, <http://dx.doi.org/10.1245/s10434-020-09161-7>.
 60. Passot G, Kim BJ, Glehen O, et al. Impact of RAS mutations in metastatic colorectal cancer after potentially curative resection: Does site of metastases matter? *Ann Surg Oncol.* 2018;25:179–87, <http://dx.doi.org/10.1245/s10434-017-6141-7>.

61. Gillern SM, Chua TC, Stojadinovic A, et al. KRAS status in patients with colorectal cancer peritoneal carcinomatosis and its impact on outcome. *Am J Clin Oncol*. 2010;33:456–60, <http://dx.doi.org/10.1097/COC.0b013e3181b4b160>.
62. Arjona-Sánchez A, Rodríguez-Ortíz L, Baratti D, et al. RAS mutation decreases overall survival after optimal cytoreductive surgery and hyperthermic intraperitoneal chemotherapy of colorectal peritoneal metastasis: a modification proposal of the peritoneal surface disease severity score. *Ann Surg Oncol*. 2019;26:2595–604, <http://dx.doi.org/10.1245/s10434-019-07378-9>.